General Information of Drug (ID: DMCSN69)

Drug Name
PT2385 Drug Info
Synonyms
ONBSHRSJOPSEGS-INIZCTEOSA-N; PT-2385; UNII-6O16716DXP; 1672665-49-4; 6O16716DXP; SCHEMBL16555810; ZINC230453533; AKOS030526641; HY-12867; PT2385,1672665-49-4, PT 2385,PT-2385; Benzonitrile, 3-(((1S)-2,2-difluoro-2,3-dihydro-1-hydroxy-7-(methylsulfonyl)-1H-inden-4-yl)oxy)-5-fluoro-; 3-{[(1s)-2,2-Difluoro-1-Hydroxy-7-(Methylsulfonyl)-2,3-Dihydro-1h-Inden-4-Yl]oxy}-5-Fluorobenzonitrile; 3-(((1S)-2,2-Difluoro-1-hydroxy-7-methanesulfonyl-2,3-dihydro-1hinden-4-yl)oxy)-5-fluorobenzonitrile; 79A
Indication
Disease Entry ICD 11 Status REF
Recurrent glioblastoma 2A00.00 Phase 2 [1] , [2]
Von hippel-lindau disease 5A75 Phase 2 [1]
Brain cancer 2A00 Investigative [3]
Cross-matching ID
PubChem CID
91754484
CAS Number
CAS 1672665-49-4
TTD Drug ID
DMCSN69

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
PT2977 DML1KTO Renal cell carcinoma 2C90 Phase 3 [1]
Drug Name Drug ID Indication ICD 11 Highest Status REF
ARO-HIF2 DMV5PEK Renal cell carcinoma 2C90 Phase 1 [4]
ISIS 222041 DMS03TR Discovery agent N.A. Investigative [5]
ISIS 222035 DMQY2EA Discovery agent N.A. Investigative [5]
ISIS 222039 DMVL1SN Discovery agent N.A. Investigative [5]
ISIS 222001 DMD7HA3 Discovery agent N.A. Investigative [5]
ISIS 222043 DM26M7E Discovery agent N.A. Investigative [5]
⏷ Show the Full List of 6 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
(5-(1-benzyl-1H-indazol-3-yl)furan-2-yl)methanol DM15P2G Discovery agent N.A. Investigative [6]
ISIS 298697 DM0WH1L Discovery agent N.A. Investigative [5]
ISIS 298744 DM8VMQ4 Discovery agent N.A. Investigative [5]
ISIS 298746 DMHOJ0Z Discovery agent N.A. Investigative [5]
ISIS 298745 DM9YMPI Discovery agent N.A. Investigative [5]
ISIS 298743 DMD3NSQ Discovery agent N.A. Investigative [5]
ISIS 298702 DM4L7NE Discovery agent N.A. Investigative [5]
ISIS 298700 DM3DE98 Discovery agent N.A. Investigative [5]
ISIS 175510 DMPAXR4 Discovery agent N.A. Investigative [5]
ISIS 298699 DMB28JW Discovery agent N.A. Investigative [5]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
HIF1-alpha messenger RNA (HIF1A mRNA) TTSN6QU HIF1A_HUMAN Inhibitor [1]
HIF2-alpha messenger RNA (EPAS1 mRNA) TTWPA54 EPAS1_HUMAN Inhibitor [2]
Hypoxia-inducible factor 2 alpha (HIF-2A) TTDMLNT EPAS1_HUMAN Inhibitor [3]

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Hypoxia-inducible factor 2: a novel target in gliomas.Future Med Chem. 2018 Sep 1;10(18):2227-2236.
4 National Cancer Institute Drug Dictionary (drug name ARO-HIF2).
5 US patent application no. 7,217,572, Modulation of HIF1.alpha. and HIF2.alpha. expression.
6 Synthesis of (aryloxyacetylamino)-isonicotinic/nicotinic acid analogues as potent hypoxia-inducible factor (HIF)-1alpha inhibitors. Bioorg Med Chem Lett. 2007 Nov 15;17(22):6305-10.